CMS reverses wound care restrictions, securing patient access to advanced treatments
The US Centers for Medicare & Medicaid Services (CMS) has withdrawn local coverage rules for certain wound treatments, ensuring patients can still access products like VENDAJE and VENDAJE AC. BioStem Technologies, the company behind these treatments, has welcomed the move as a positive step for clinicians and patients alike.
The withdrawn rules, known as Local Coverage Determinations (LCDs), previously governed skin substitute grafts and cellular products used for diabetic foot ulcers and venous leg ulcers. Had they remained in place, these LCDs could have restricted access to treatments such as BioStem’s VENDAJE and VENDAJE AC.
BioStem confirmed that the withdrawal will not disrupt patient access to its technology. The company also reaffirmed its commitment to evidence-based practices, pledging to keep investing in clinical research. This will help demonstrate the effectiveness of its proprietary wound care solutions. Jason Matuszewski, CEO and Chairman of BioStem, acknowledged the efforts of clinical partners, policymakers, and advocacy groups in shaping the reimbursement landscape. Their collaboration played a key role in securing continued access to these advanced treatments.
With the LCDs no longer in effect, patients requiring VENDAJE and VENDAJE AC will face no new barriers to treatment. BioStem will keep focusing on clinical data to support the long-term use of its technology. The company’s approach aims to maintain stability for both patients and healthcare providers.
